Ispita-nitsite, vrz osnova CYP2C19 definiranite metabolichki fenotipo-vi, bea stratifitsirani vo tri razlichni grupi: brzi metabolizeri(BM: khomozigoti za normalen CYP2C19 alel), sredno brzi meta-bolizeri (SBM: kheterozigoti za varijanten CYP2C19 alel) i sporimetabolizeri (SM: khomozigoti za varijanten CYP2C19 alel).REzUlTATI I DISKUSIJASite 198 ispitanitsi (127 mashki (64,14%) i 71 zhenski (35,85%);sredna vozrast 60,57+- 8,49 godini), koi se vklucheni vo studijata beaod bela rasa. Populatsionite frekfentsii na CYP2C19 *2; *3 i *4varijantnite aleli,odgovorni za poremetuvanja vo normalniot me-tabolizam na klopidogrelot iznesuvaat: 18.69; 0.51 i 0.51, so-odvetno. Pri genotipizatsijata na studiskiot primerok ne beshedetektiran CYP2C19*5 varijantniot alel, zaradi shto ovoj poli-morfizam ne e vkluchen vo ponatamoshnite analizi. Genotipskatadistributsija i alelnata frekfentsija na ostanatite analiziraniCYP2C19 polimorfizmi e prikazhana na Tabela 1. Utvrdenite geno-tipski distributsii za site polimorfni varijanti se vo ramkitena prifatlivite otstapuvanja spored Hardy - Weinberg equilibriumtestot. Prevalentsata na CYP2C19 metabolichkite fenotipovi,definirani vrz osnova na CYP2C19*2,*3 i *4 polimorfizmite, voRepublika Makedonija, e pretstavena na Tabela 2.347fifth congress of phArmAcy of mAcedoniA with internAtionAl pArticipAtionMacedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACEUTICAL CHEMISTRY / BIOMOLECULAR SCIENCESposter presentationsTabela 1. Genotipska distributsija i alelna frekfentsija naCYP2C19 genetskite varijanti vo R.Makedonija. * wt/wt - khomozigot na normalen alel; wt/mut - kheterozigot zavarijanten alel; mut/mut - khomozigot na mutanten alel; wt-normalen, mut-mutanten alelGenetskata varijanta na CYP2C19*2 e najzastapena (varijatsii vointerval 9-26%) kaj belata populatsija; *3 e relativno retka (0-2%),dodeka pak frekfentsijata na *4 iznesuva 0.6%. Genetskitevarijanti na CYP2C19*2 i *3 sochinuvaat priblizhno 83% od siteSM alele i se odgovorni za okolu 90% SM fenotipovite kaj belatarasa3,4. Na Tabela 3 e prikazhana distributsijata na CYP2C19*2 i *3kaj ispitanitsite od R.Makedonija vo sporedba so literaturnitepodatotsi za distributsijata kaj drugite etnichki grupi od svetot3,4,5.zAKlUChOKFrekfentsiite na CYP2C19 varijantnite aleli vo nashatapopulatsija se slichni so onie kaj ostanatite populatsii od belatarasa. Frekfentsijata na SM fenotip vo R.Makednija iznesuva4.55%, definirano vrz osnova samo na CYP2C19*2 genetskiotpolimorfizam. Ovie rezultati imaat za tsel da pridonesat voistrazhuvanjata za individualizatsija na terapijata so klopidogrelvo nashata drzhava.Tabela 2. Prevalentsa na CYP2C19 definiranite metabolnitefenotipi vo populatsija od R.MakedonijaTabela 3. Distributsija na CYP2C19*2 i *3 varijantnite aleli vorazlichni etnichki populatsii od belata rasaKORISTENA lITERATURA1. Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., et.al. (2007), Variability inindividual responsiveness to clopidogrel. Clinical implications, management, andfuture perspectives. J Am Coll Cardiol . 49:1505-16.2. Bozina, N., Granic, P., Lalic, Z., et al. (2003), Genetic polymorphisms of CytochromP450:CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croatian Medical Jour-nal. 44 (4) 425-4283. Rosemary,J and Adithan,C. (2007) , The Pharmacogenetics of CYP2C9 andCYP2C19: Ethnic Variation and Clinical Significance. Current Clinical Pharmacology.2: 93-1094. Mega ,J.L., Close, S.L., Wiviott, S.D., et al. (2009), Cytochrome p-450 polymorphismsand response to clopidogrel. N Engl J Med. 360(4):354-62.5. Buzoianu,A.D.,Trifa,A.P., Popp,R.A.,et al. (2010). Screening for Cyp2C19*2,*3 and *4gene variants in a Romanian population study group. FARMACIA. 58(6): 806-817thymidylAte synthAse enhAncerregion (tser) 2r/3r polymorphismsAs An independent risk fActor forcolorectAl cAncer in mAcedoniAnpopulAtionKapedanovska Nestorovska A1, Serafimoska Z1,Sterjev Z1, Josifovski T2, Petrusevska N3, SuturkovaL1, Dimovski AJ11Center for Bimolecular Pharmaceutical Analysis, Faculty of Pharmacy,2Clinic for Abdominal Surgery,3Institute of Radiotherapy and Oncology, Faculty of Medicine,University "Ss Cyril and Methodius", Skopje, Republic of MacedoniabAckgroundThymidylate synthase (TYMS) is a key enzyme in folate metabolism, animportant pathway in carcinogenesis. TYMS catalyzes the conversionof dUMP to dTMP, an essential nucleotide needed for DNA synthesisand repair1. The TYMS gene has a variable number of tandem repeats(VNTR; 2R or 3R) polymorphisms in the thymidylate synthase enhancerregion (TSER), a G/C single nucleotide polymorphism within the secondrepeat sequence of 3R (3G or 3C), and a 6 bp insertion/deletionpolymorphism (6 bp or 0 bp) in the TYMS 3'-untranslated region (3'-UTR)2. Although the protective effect of the TYMS TSER tandemrepeat polymorphism in colon cancer chemotherapy has been well348PETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOMakedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKA KhEMIJA / BIOMOLEKULARNI NAUKIposter prezentatsiistudied, the association between TSER polymorphisms and risk forcolorectal cancer has remained elusive 3-5.AimTo investigate whether TYMS TSER 2R/3R independently predicts riskof CRC in a population based case -control study.mAteriAls And methodsThe case group consisted of 327 patients with cliniopatologicaly con-firmed CRC (178 male and 144 female; mean age 60, 27 +- 11, 08). Thecontrol group was composed of 105 blood donors (40 male and 65 fe-male; mean age 74.52 +- 10.46). Genomic DNA was obtained from pe-ripheral blood or tumor using Proteinase Kdigestion/phenol-chloroform extraction and ethanol precipitation.The TYMS TSER polymorphism was analyzed by polymerase chainreaction (PCR) using a forward (5'- TCC GAG CCG GCC ACA GGC AT-3')and a reverse (5'-GCC GAA GGG GTC CTG CCA-3') primer. Thegenotypes were evaluated by electrophoresis on a 10% ethidiumbromide-stained polyacrylamide gel (PAGE). Fragments of 109 and 137bp corresponded to the 2R and 3R allele, respectively ( Fig. 1).Hardy-Weinberg equilibrium was tested with the X2 statistic for thegoodness-of-fit (1 df). Univariate analysis was performed for age, (<50vs >=50 years, <60 vs >=60 years, ) gender, tumor location (right sided vsleft sided), TNM (I + II vs III+IV ) stages of the tumor in patients and con-trols, stratified by the genotypes of the TYMS gene. The statisticalsignificance of the differences between groups was calculated by thechi-square and Fischer exact test. Odds ratios (ORs) were calculatedand were given within 95% confidence intervals (CI). Factors with p<=0.05 were considered statistically significant.results And discussionAmong the 327 patients and 105 controls, the TYMS TSER *3R allelefrequencies were 0.54 and 0.63 respectively, and TSER *2R allelefrequencies were 0.44 and 0.38, respectively. The TYMS TSER genotypefrequencies within the patients and control groups are presented inTable 1. Both study groups were in Hardy-Weinberg equilibrium forthe distribution of the TYMS TSER 2R/3R polymorphism.Compared with 3R/3R genotype, patients with TYMS 2R/2R genotypehad significantly increased risk of CRC (p=0.046) with adjusted relativerisk of 2.009 (95% C.I. =1.004-4.022). Additionally, the TYMS TSER * 3Rallele was associated with lower risk of CRC in a co-dominant [2R/2Rvs. 3R/3R, (p=0.046) and 2R/2R vs. 2R/3R (p=0.032)] and dominant[2R/2R vs. 2R/3R+3R/3R, (p=0.0264)] model of statistical analysis(Table1). No significant differences in frequencies of the TYMS TSERgenotypes were found in CRC patients stratified by theclinicopathologic variables (age, gender, tumor stage or localization).In contrast with the findings for CRC, reporting no association orstatistically significant association of 3R/3R genotype and increasedrisk of CRC, the results from our study are consistent with studies re-porting association with acute lymphocyte leukemia and malignantlymphoma, and lungh cancer 3-5.Since TS *2R allele is related to lower plasma folate levels, and sincehigh folate levels reduce DNA damage or facilitate DNA repair, then itis expected that 2R/2R genotype would be associated with anincreased risk of cancer.conclusionTo the best of our knowledge, the present case-control study is thefirst one to report an association between TYMS 2R/2R genotype andincreased risk of colorectal cancer. The results of this study suggestthat the effect of the TSER polymorphism and folate pathway on col-orectal cancer may be specific to Macedonian ethnic group.Fig.1. PAGE electrophoresis following PCR amplification of the TYMSTSER 2R/3R polymorphism: 1, 2, 6-3R/3R genotype; 3,7-2R/3R geno-type; 4,5-2R/2Rgenotype; 8-blank; M-50bp DNA ladderTable 1. Association of TYMS TSER 2R/3R polymorphism with CRCrisk in Macedonian populationAbreviations: a- 3R/3R as reference; b-2R/2R as refferencereferences1. Chen,J., Hunter,D.J., Stampfer,M.J., Kyte,C., Chan,W., Wetmur,J.G., Mosig,R.,Selhub,J. and Ma,J. (2003) Polymorphism in the thymidylate synthase promoterenhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol.Biomarkers Prev., 12, 958--962.2. Curtin, K.,, Ulrich, C.M., Samowitz, W.S., Bigler,J., Caan,B., John D. Potter.J.D.,Slattery,M. (2007) Thymidylate synthase polymorphisms and colon cancer:Associations with tumor stage, tumor characteristics and survival. Int. J. Cancer.,120, 2226-2232.3. Shi,Q., Zhang, Z., Neumann,A.S., Li,G., Margaret R.Spitz,M.R., Wei,Q. (2005) Case--control analysis of thymidylate synthase polymorphisms and risk of lung cancer.Carcinogenesis, 26 (3),649--656,4.Jensen,S.A., Ben Vainer,B., Jens Benn Sshrensen,J.B. (2006) The prognosticsignificance of thymidylate synthase and dihydropyrimidine dehydrogenase incolorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int. J.Cancer., 120, 694-7015. Skibola,C.F., Smith,M.T., Hubbard,A. et al. (2002) Polymorphisms in the thymidylatesynthase and serine hydroxymethyltransferase genes and risk of adult acutelymphocytic leukemia. Blood, 99, 3786--3791.349fifth congress of phArmAcy of mAcedoniA with internAtionAl pArticipAtionMacedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACEUTICAL CHEMISTRY / BIOMOLECULAR SCIENCESposter presentationsTIMIDIlAT SINTETAzA (2r/3r)GENETSKA VARIJANTA KAKONEzAVISEN RIzIK FAKTOR zA RAzVOJNA KOlOREKTAlEN KARTsINOMVO REPUblIKA MAKEDONIJAKapedanovska Nestorovska A1, Serafimoska Z1,Sterjev Z1, Josifovski T2, Petrushevska N3,Shuturkova Lj1, Dimovski A.J.11Tsentar za Biomolekularni Farmatsevtski Analizi,Farmatsevtski Fakultet,2Klinika za Digetsivna Khirurgija,3Institut za Radioterapija i Onkologija, Meditsinski Fakultet,Univerzitet "Sv. Kiril i Metodij", Skopje, Republika MakedonijaVOVEDTimidilat sintetaza (TYMS) e najznachajniot enzim vo folatniot me-tabolizam koj pretstavuva eden od kluchnite chekori vo protsesot nakantserogenza. Toj ja katalizira biosintezata na timidin mono-fosfat (dTMP), nukleotid potreben za sinteza i reparatsija naDNA molekulata1. Dosega se identifikuvani tri polimorfizmi naTYMS genot: 2R/3R polimorfizam na 28 bp tandem povtoruvachki se-kventsi vo promoter regionot (TSER 2R/3R), G/C ednonukleotidenpolimorfizam vo vtorata od trite povtoruvachki sekventsi na 3R(3G/3C) i polimorfizam na insertsija/deletsija na 6 bp (6 bp / 0 bp)vo TYMS 3'-netranslatsioniot region (3'-UTR)2.